Biogen Finalizes RayThera Acquisition and Unveils Robust Q2 Results, Propelling Growth Outlook

Biogen (Nasdaq: BIIB) confirmed on August 6, 2026 that it has completed its acquisition of RayThera Inc., bringing multiple immunology assets—including one program that entered Phase 1 development in July—under its umbrella. Biogen described the milestone as strengthening its immunology portfolio and advancing its long‑term growth strategy.

Just days before, on July 29, Biogen released its second‑quarter 2026 earnings. The company delivered total revenue of approximately $2.74 billion—a 3% year‑over‑year increase—and Non‑GAAP diluted EPS of $3.60, topping analyst estimates. Biogen upgraded its full‑year 2026 revenue projection to a mid‑single‑digit percentage increase, reversing earlier expectations for a decline. Underlying adjusted EPS guidance (excluding acquisition‑related dilution) was raised to a range of $15.85 to $16.85 per share.

RayThera Acquisition Completed

On August 6, Biogen announced the closing of its acquisition of RayThera Inc., a privately held biotech focused on small‑molecule immunology. The deal brings several novel assets into Biogen’s pipeline, including a lead candidate that commenced Phase 1 trials in July 2026. Biogen highlighted the move as a strategic expansion into immune‑mediated conditions and praised RayThera’s scientific foundation.

Q2 Performance and Guidance Reversal

Biogen’s Q2 performance exceeded expectations, with total revenue reaching $2.74 billion and adjusted EPS of $3.60. Growth drivers included strong sales of newer products like Empaveli, Syfovre, Skyclarys, Qalsody, Zurzuvae, Spinraza (high‑dose regimen), and contributions from the Alzheimer’s drug Leqembi. These growth items increasingly offset declining sales in its legacy multiple sclerosis portfolio, which continues to face competitive pressure and biosimilar erosion.

As a result, Biogen reversed its earlier guidance anticipating a 2026 revenue decline and now projects a mid‑single‑digit revenue increase for the year. The company also raised its underlying (pre‑acquisition impact) adjusted EPS guidance to $15.85–$16.85, up from the prior $15.25–$16.25 range.

Strategic and Financial Implications

The closing of the RayThera deal reinforces Biogen’s strategy to diversify beyond neurology-focused therapies into immunology. Having a Phase 1 candidate already progressing adds tangible pipeline value. At the same time, better-than-expected Q2 results and streamlined outlook demonstrate stronger business momentum amid shifting product mix and recently acquired assets.

What to Monitor Next

• Progress of the RayThera lead asset through Phase 1 trials and potential expansion of immunology programs.
• Upcoming registrational readouts from late-stage assets, including litifilimab (SLE), felzartamab (AMR), zorevunersen (Dravet syndrome), and diranersen (Alzheimer’s), expected over the next four quarters.
• Financial impact of acquisition-related charges, integration costs, and operating expenses as Biogen executes on its growth strategy.

Biogen’s stock was trading at $227.53 as of September 23, 2026, reflecting this favorable performance and strategic expansion in its pipeline and commercial portfolio.